Adalimumab treatment of resistant chondrocalcinosis; [Tratamiento con adalimumab de la condrocalcinosis resistente]
| dc.contributor.author | Tastekin F. | |
| dc.contributor.author | Aksu K. | |
| dc.date.accessioned | 2024-08-31T07:42:29Z | |
| dc.date.available | 2024-08-31T07:42:29Z | |
| dc.date.issued | 2024 | |
| dc.department | Ege Üniversitesi | en_US |
| dc.description.abstract | In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD. © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología | en_US |
| dc.identifier.doi | 10.1016/j.reuma.2024.06.003 | |
| dc.identifier.issn | 1699-258X | |
| dc.identifier.scopus | 2-s2.0-85199130783 | en_US |
| dc.identifier.scopusquality | Q3 | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.reuma.2024.06.003 | |
| dc.identifier.uri | https://hdl.handle.net/11454/103904 | |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Ediciones Doyma, S.L. | en_US |
| dc.relation.ispartof | Reumatologia Clinica | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.snmz | 20240831_U | en_US |
| dc.subject | Adalimumab | en_US |
| dc.subject | Calcium pyrophosphate | en_US |
| dc.subject | Chondrocalcinosis | en_US |
| dc.subject | Tumor necrosis factor-alpha | en_US |
| dc.title | Adalimumab treatment of resistant chondrocalcinosis; [Tratamiento con adalimumab de la condrocalcinosis resistente] | en_US |
| dc.type | Article | en_US |
